Commercialization of Embryonic Kidney Cell Lines

胚胎肾细胞系的商业化

基本信息

批准号：
7219068
负责人：
JEFFREY L BARNES
金额：
$ 14.88万
依托单位：
PROBETEX, INC.
依托单位国家：
美国
项目类别：
财政年份：
2007
资助国家：
美国
起止时间：
2007-08-01 至 2009-01-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7219068
关键词：
Address Adult American Antibodies Arts Biomedical Engineering Cell Line Cell Separation Cells Cellular biology Characteristics Cleaved cell Cloning Coculture Techniques Collaborations Condition Conditioned Culture Media Development Diabetes Mellitus Differentiation and Growth Disruption Dissection Edetic Acid Embryo Funding Genetic Goals Growth Health Sciences Human Resources Immunohistochemistry In Vitro Institutes Kidney Kidney Diseases Licensing Magnetism Maintenance Mediating Mesenchymal Mesenchyme Metanephric Diverticulum Modeling Mus Nephrology Nephrons Phase Phenotype Polymerase Chain Reaction Preparation Primordium Production Proteomics Protocols documentation Publishing Quality Control Range Rattus Recommendation Recording of previous events Renal Tissue Reporting Research Research Personnel Research Priority Resources Reverse Transcriptase Polymerase Chain Reaction SCID Mice Sampling Signal Transduction Small Business Funding Mechanisms Small Business Innovation Research Grant Societies Stem cells Strategic Planning Structure Surface System Techniques Testing Texas Tissues Universities Work base blastomere structure cell bank cell preparation cell type commercialization design embryonic stem cell established cell line human disease implantation in vivo insight kidney cell mesangial cell nephrogenesis progenitor programs repository research study stem subcutaneous symposium

项目摘要

DESCRIPTION (provided by applicant): There is a crucial need for increases in resources and manpower in research in kidney disease. Probetex was founded as a "Renal Research Resource Company" to create a repository of "off the-shelf" tissue products to provide readily available samples and help investigators to quickly and efficiently explore their ideas on established and standardized models or identified cases of human disease. Part of this goal is to create a repository of kidney cell lines to supplement its portfolio of renal tissue products. Indeed, the isolation, cloning, maintenance, and characterization of renal progenitor cells is identified as a research priority in a Report of the Strategic Planning Conferences sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases and the Council of American Kidney Societies. Included in these priorities are initiatives to 1) develop new organotypic in vitro culture models and 2) develop conditions to permit commitment of stem cells into renal progenitors, and then the maintenance of these differentiated cell lines. The basis of this Phase I application (in collaboration with the University of Texas Health Science Center at San Antonio) is to address the above priorities by defining growth and differentiation conditions for three existing kidney progenitor cell lines derived from mouse and rat embryonic primordia and to isolate and characterize new cell lines from developing embryonic kidney. Specific aims are: Aim 1. To characterize the differentiation potential of embryonic metanephric mesenchymal (MM) and ureteric bud (UB) cell lines derived from kidney primordia. Differentiation conditions include growth in co-culture, in specialized conditioned media, and after implantation of the cells individually and in combination in SCID mice. Expression analysis will be conducted using immunohistochemistry and RT-PCR to validate expanded set of expression markers for specific cell types and differentiation states of the cells. Aim 2. To isolate and characterize new embryonic cell lines derived from the nephrogenic zone of embryonic metanephric kidney and characterize the cells using criteria as outlined above; Aims 3 and 4 are designed to establish an Embryonic Kidney Cell Bank and Commercialization Plan for expansion of new cell lines, large-scale production protocols for kidney cell propagation, out-sourcing, and licensing with the intent to expand the scope of cell lines in the Probetex's repository that are available to the company's investigator/ customers.

描述（由申请人提供）：肾脏疾病研究迫切需要增加资源和人力。 Probetex 成立时是一家“肾脏研究资源公司”，旨在创建“现成”组织产品存储库，提供现成的样本，并帮助研究人员快速有效地探索他们对已建立的标准化模型或已识别的人类疾病病例的想法。该目标的一部分是创建肾细胞系库，以补充其肾组织产品组合。事实上，在国家糖尿病、消化和肾脏疾病研究所以及美国肾脏学会理事会主办的战略规划会议报告中，肾脏祖细胞的分离、克隆、维护和表征被确定为研究重点。这些优先事项包括以下举措：1）开发新的器官型体外培养模型，2）开发允许干细胞定向分化为肾祖细胞的条件，然后维持这些分化的细胞系。该一期申请的基础（与圣安东尼奥德克萨斯大学健康科学中心合作）是通过定义源自小鼠和大鼠胚胎原基的三种现有肾祖细胞系的生长和分化条件来解决上述优先事项，并从发育中的胚胎肾中分离并表征新的细胞系。具体目标是：目的 1. 表征源自肾原基的胚胎后肾间充质 (MM) 和输尿管芽 (UB) 细胞系的分化潜力。分化条件包括在共培养物中、在专门的条件培养基中以及将细胞单独或组合植入SCID小鼠后的生长。将使用免疫组织化学和 RT-PCR 进行表达分析，以验证特定细胞类型和细胞分化状态的扩展表达标记集。目标 2. 分离和表征源自胚胎后肾肾的肾发生区的新胚胎细胞系，并使用上述标准表征细胞；目标 3 和 4 旨在建立胚胎肾细胞库和商业化计划，以扩展新的细胞系、肾细胞增殖的大规模生产方案、外包和许可，旨在扩大细胞系的范围Probetex 的存储库可供公司的研究人员/客户使用。